CA2111199C - Pharmaceutical formulations of osteogenic proteins - Google Patents
Pharmaceutical formulations of osteogenic proteins Download PDFInfo
- Publication number
- CA2111199C CA2111199C CA002111199A CA2111199A CA2111199C CA 2111199 C CA2111199 C CA 2111199C CA 002111199 A CA002111199 A CA 002111199A CA 2111199 A CA2111199 A CA 2111199A CA 2111199 C CA2111199 C CA 2111199C
- Authority
- CA
- Canada
- Prior art keywords
- composition
- poly
- protein
- lactic acid
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
Abstract
A composition comprising a pharmaceutically acceptable admixture of an osteogenic protein; a polymer matrix compo-nent selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid;
and an osteogenic protein-sequestering material.
and an osteogenic protein-sequestering material.
Description
TITLE OF THE INVENTION
PHARMACEUTICAL FORMULATIONS OF OSTEOGENIC PROTEINS
BACKGROUND OF THE INVENTION
The subject invention relates to the f ield of osteogenic proteins and pharmaceutical formulations thereof. More particularly, the subject invention involves pharmaceutical formulations designed to sequester osteogenic protein in-situ for a time sufficient to allow the protein to induce cartilage and/or bone formation.
Osteogenic proteins are those proteins capable of inducing, or assisting in the induction of cartilage and/or bone formation.
Many such osteogenic proteins have in recent years been isolated and characterized, and some have been produced by recombinant methods. For example, so-called bone morphogenic proteins (BMP) have been isolated from demineralized bone tissue (see e.g. Urist U.S. 4,455,256); a number of such'BMP proteins have been produced by recombinant techniques (see e.g. Wang et al. U.S. 4,877,864 and Wang et al. U.S. 5,013,549); a family of transforming growth factors (TGF-a and TGF-0) has been.identified as potentially useful in the treatment of bone disease~(see e.g. Derynck et al., EP
154,434); a protein designated Vgr-1 has been found to be expressed at high levels in osteogenic cells (see Lyons et al. (1989) Proc.
Nat' l. Acad. Sci. USA 86, 4554-4558); and proteins designated OP-1, COP-5 and COP-7 have purportedly shown bone inductive activity (see Oppermann, et al. U.S. 5,001,691).
Various attempts have been made at developing formulations designed to deliver osteogenic proteins to a site where induction of bone formation is desired. For example, certain polymeric matrices such'as acrylic ester polymer (Urist, U.S. 4,526,909) and lactic acid polymer (Urist, U.S. 4,563,489) have been utilized, but these formulations do not sequester the osteogenic protein for a time sufficient to optimally induce bone formation and further have been found to erode too slowly for optimal bone formation.
A biodegradeable matrix of porous particles for delivery of an osteogenic protein designated as OP is disclosed in Kuberasampath, U.S. 5,108,753. While US 5,108,753 discloses that a successful carrier for OP
must bind the protein, act as a slow release delivery system, accommodate each step of the cellular response during bone development, and protect the protein from nonspecific proteolysis, no formulations are suggested which contain components that specifically sequester the OP at the site where bone formation is desired.' Okada et al., US 4,652,441, US 4,711,782, US 4,917,893 and US
5,061,492 and Yamamoto et al., US 4,954,298 disclose a prolonged-release microcapsule comprising a polypeptide drug and a drug-retaining substance encapsulated in an inner aqueous layer surrounded by a polymer wall substance in an outer oil layer.
Al:though bone morphogenic protein is listed as a polypeptide capable of such a formation, microencapsulation of osteogenic proteins prevents controlled release of such protein suffici-ent for optimal bone formation.
Collagen matrices have also been used as delivery vehicles for osteogenic proteins (see e.g. Jeffries, U.S. 4,394,370), but collagen frequently causes undestrable antigenic reactions in patients. Therefore, there remains a need for a pharmaceutical formulation capable of sequestering osteogenic proteins at a site where induction of bone formation is desired for a time sufficient to allow safe, effective induction of such bone formation.
SUMMARY OF THE INVENTION
In one embodiment, the subject invention provides a composition comprising a pharmaceutically acceptable admixture of an osteogenic protein; a~polymer matrix component selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid; and an osteogenic protein-sequestering alkylcellulose.
PHARMACEUTICAL FORMULATIONS OF OSTEOGENIC PROTEINS
BACKGROUND OF THE INVENTION
The subject invention relates to the f ield of osteogenic proteins and pharmaceutical formulations thereof. More particularly, the subject invention involves pharmaceutical formulations designed to sequester osteogenic protein in-situ for a time sufficient to allow the protein to induce cartilage and/or bone formation.
Osteogenic proteins are those proteins capable of inducing, or assisting in the induction of cartilage and/or bone formation.
Many such osteogenic proteins have in recent years been isolated and characterized, and some have been produced by recombinant methods. For example, so-called bone morphogenic proteins (BMP) have been isolated from demineralized bone tissue (see e.g. Urist U.S. 4,455,256); a number of such'BMP proteins have been produced by recombinant techniques (see e.g. Wang et al. U.S. 4,877,864 and Wang et al. U.S. 5,013,549); a family of transforming growth factors (TGF-a and TGF-0) has been.identified as potentially useful in the treatment of bone disease~(see e.g. Derynck et al., EP
154,434); a protein designated Vgr-1 has been found to be expressed at high levels in osteogenic cells (see Lyons et al. (1989) Proc.
Nat' l. Acad. Sci. USA 86, 4554-4558); and proteins designated OP-1, COP-5 and COP-7 have purportedly shown bone inductive activity (see Oppermann, et al. U.S. 5,001,691).
Various attempts have been made at developing formulations designed to deliver osteogenic proteins to a site where induction of bone formation is desired. For example, certain polymeric matrices such'as acrylic ester polymer (Urist, U.S. 4,526,909) and lactic acid polymer (Urist, U.S. 4,563,489) have been utilized, but these formulations do not sequester the osteogenic protein for a time sufficient to optimally induce bone formation and further have been found to erode too slowly for optimal bone formation.
A biodegradeable matrix of porous particles for delivery of an osteogenic protein designated as OP is disclosed in Kuberasampath, U.S. 5,108,753. While US 5,108,753 discloses that a successful carrier for OP
must bind the protein, act as a slow release delivery system, accommodate each step of the cellular response during bone development, and protect the protein from nonspecific proteolysis, no formulations are suggested which contain components that specifically sequester the OP at the site where bone formation is desired.' Okada et al., US 4,652,441, US 4,711,782, US 4,917,893 and US
5,061,492 and Yamamoto et al., US 4,954,298 disclose a prolonged-release microcapsule comprising a polypeptide drug and a drug-retaining substance encapsulated in an inner aqueous layer surrounded by a polymer wall substance in an outer oil layer.
Al:though bone morphogenic protein is listed as a polypeptide capable of such a formation, microencapsulation of osteogenic proteins prevents controlled release of such protein suffici-ent for optimal bone formation.
Collagen matrices have also been used as delivery vehicles for osteogenic proteins (see e.g. Jeffries, U.S. 4,394,370), but collagen frequently causes undestrable antigenic reactions in patients. Therefore, there remains a need for a pharmaceutical formulation capable of sequestering osteogenic proteins at a site where induction of bone formation is desired for a time sufficient to allow safe, effective induction of such bone formation.
SUMMARY OF THE INVENTION
In one embodiment, the subject invention provides a composition comprising a pharmaceutically acceptable admixture of an osteogenic protein; a~polymer matrix component selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid; and an osteogenic protein-sequestering alkylcellulose.
WO 93/00050 PC.'T/US92/05309 21.11199 In another embodiment, the subject invention provides a composition comprising a pharmaceutically acceptable admixture of an osteogenic protein; a polymer matrix component selected from the group consisting of poly(lactic acid), poly(giycolic acid), and copolymers of lactic acid and glycolic acid; and an osteogenic protein-sequestering agent selected from the group consisting of hyaluronic acid, alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer, and poly(vinyl alcohol).
In another embodiment, the subject invention provides a composition comprising polymeric particles having a spherical diameter of between about 150 and 850 microns and a porosity such that the surface area of the particles is between about 0.02 and 4 m2/g, wherein the polymer is selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid; optionally in admixture with osteogenic protein.
In yet another embodiment, the subject invention provides a composition comprising a pharmaceutically acceptable admixture of osteogenic protein and an effective solubilizing amount of a member selected from the group consisting of arginine, histidine, dextran sulfate, gamma-amino butyric acid, beta-amino propionic acid, glycine-glycine, glycine ethyl ester, histidine ethyl ester, lysine methyl ester, arginine methyl este'r; guanidine, 'sodium chloride, heparin, lysine, beta-alanine ethyl ester and agmatine.
DETAILED DESCRIPTION OF THE INVENTION
The osteogenic.proteins useful in the practice of the subject invention are well known to those skilled in the art and include those discussed above. The preferred osteogenic proteins for use herein are those of the BMP class identified as BMP-1 through BMP-8 in U.S. 4,877,864; U.S. 5,0131649; WO 90 , /11366 published October 4, 1990; and WO 91/18098 published November 28, 1991. The most preferred is BMP-2, the mature protein sequence beginning with the ~i... ,. . .. _ . . . _ , ..., ... ., ri. . .. ..... ...... . . r . . . ., .,..1A., ";. ,...i ,.5.... .... ... . . ...., _.. . , . - .... .
-amino acid Gln at nucleotide 1202 and ending with the amino acid Arg at nucleotide 1543, as described in detail in the '649 patent.
Of course, combinations of two or more of such osteogeriic proteins may be used, as may fragments of such proteins that also exhibit osteogenic activity and heterodimeric forms of such proteins.
Recombinant proteins are preferred over naturally occurring isolated proteins. The amount of osteogenic protein useful herein is that amount effective to stimulate increased osteogenic activity of infiltrating progenitor cells, and will depend upon the size and nature of the defect being treated as discussed in more detail below, such amounts being orders of magnitude less than the amount of polymer matrix employed, preferably in the range of 1-50 g of protein for each 10 mg of polymer matrix employed and more preferably in the range of 0.5 - 5 g protein for each mg of polymer matrix employed.
The osteogenic proteins,can be utilized in the form of a pharmaceutically acceptable solution or in lyophilized form. In either case it is optimal to stabilize and solubilize the osteogenic protein, preferably at concentrations of at 'least 1 mg/mi so that a pharmaceutically effective.amount of protein can be delivered without undue volumes of carrier solution being necessary. However, a problem exists in that osteogenic proteins, particularly those of the BMP fami2yy have proven to be difficult to solubilize. As detailed in the examples below, it has been discovered that amino acids having a net positive charge (e.g."net 1+ species such as arginine, histidine, lysine and the ethyl esters of glycine and beta-alanine), preferably a net 2+ charge (e.g. the ethyl ester of histidine, the methyl esters of lysine and arginine, and agmatine) , are useful in this regard. Amino acids having a net zero charge are useful in this regard provided that the positive charge of the compound is sufficiently distant (at least 2-3 CH2 units away) from the"neutralizing negative charge (e.g. net neutral species such as gamma-amino butyric acid, beta-amino propionic acid and glycine-glycine dipeptide). Other solubilizing agents useful WO 93/00050 2111199 PC.'i /US92/0530g herein include dextran sulfate, guanidine, heparin and sodium chloride. For use in solubilizing BMP-2, the preferred solubilizing agents are arginine and histidine (including esters thereof). Arginine is used in concentrations of about 50-600 mM, preferably 300-500 mM. Histidine may be added to arginine to solubilize BMP-2, in concentrations of about 1-100 mM, preferably 10-50 mM. When histidine is used alone as a solubilizing agent, it is used in concentrations of about 50-600'mM, preferably 300-500 mM. Various well known methods may be used to compound the osteogenic protein and solubilizing agents for use herein, including but not limited to ultrafiltration, dialysis, gel filtration, and hydrophobic interaction chromatography.
The polymer matrix component useful in the practice of the subject invention is a polymeric material that can be formed into porous particles as described below thereby providing in-situ scaffolding for the osteogenic protein, while having biodegradable properties allowing for replacement by new bone growth. Examples are aol=1rmers of amino acids, orthoesters, anhydrides, propylene-cou-fumarates, or a polymer of one or more a-hydroxy carboxylic acid monomers, e.g. a-hydroxy acetic acid (glycolic acid) and/or a-hydroxy propionic acid (lactic acid). The latter can be employed in its d- or 1- form, or as a racemic mixture, the racemic mixture being preferred. When a copolymer tSf-lactic acid,and glycolic acid is employed (PLGA), the molar ratio of monomers can range from 1:99 to 99:1 depending upon the desired bioerosion lifetime which in turn depends upon the clinical indication being addressed, as more than 50% of either monomer gives longer bioerosion lifetime (slower biodegradation). The molecular weight of the polymer can range from about 1, 000 to 100,000 with 30, 000-50, 000 being preferred when a 50:50 copolymer is employed. The higher the molecular weight the slower the biodegradation.
The polymeri.c'matrix component of the subject invention is used in the form of highly porous to hollow (with surface porosity) particles, hereinafter collectively referred to as "porous particles." These porous particles are generally spherical having diameters of 150 to 850 microns. This particle size creates sufficient spacing between particles to allow mammalian osteoprogenitor cells to infiltrate and be positively influenced by the osteogenic protein (evidenced by an increase in osteogenic activity/bone growth rate).
While it has generally been postulated that particles suitable as matrices for delivery of osteogenic proteins should be porous, the extent of porosity necessary to optimally induce bone formation has not previously been studied. The present inventors have discovered that the average surface area per porous particle is critical to optimize bone formation. Specifically, porous particles useful in bone formation according to the present invention should have an average surface area of from about 0.02 to 4 m2/g. The present inventors have further discovered that it is possible to produce porous particles having the desired surface area by introducing a "porosigen" (composition capable of imparting porosity by increasing particle surface area) into the solution used to produce the porous particles. It is also possible to control the bioerosion rate by subjecting the porous partit:les to sterilizing doses of y radiation. The higher the 7 radiation dose, the faster the bioerosion.
The method of producing porous particles in accordance with the subject invention and discttssed hereinbelow results in particles having a porosity such that the surface area of the particles is increased about 2-250 fold over the surface area of non-porous particles of comparable size. More specifically, e.g., non-porous PLGA particles having an average size of 400 m have a surface area of 0.018 m2/g. In contrast, PLGA particles useful in the subject invention made utilizing 50% NaCl as a porosigen have a surface area of between about 0.2 and 0.6 mZ/g; and particles made using sucrose as a porosigen have a surface area of between about 0.04 and 0.09 m2/g as 'described! in Example 1. PLGA particles' of the present invention made using liquid porosigen with homogenization as described in Example 2 have a surface area of between about 0.02 . .. .. . .., ,...
= :
..:,.,.x...:, .-., ,-:...rr.,,. ... -:...F . . .,.., . . _-..__. . ......... ..............,......,. .. .,;- . ..,...._. , , ,-. .
. . =. . . a. .,.: ,.,. ..:.., ...=,.....,,. .. _ ... .. , T .
~, . . , ,,. , _.... ,.
and 4 mz/g.
A preferred method of production of the porous particles of the invention is, generally speaking, a solvent evaporation process comprising dissolving the polymer (in e.g. CH2C12), and adding a porosigen such as NaCI, mannitol or sucrose in solid and/or liquid form. When porosigen is added in solid form, the matrix-porosigen solution takes the form of a suspension. Another preferred method of production of the porous particles of the invention is a solvent extraction method, wherein the porosigen is added in liquid form with concomitant homogenization. When porosigen is added in liquid form with homogenization, the matrix-porosigen solution takes the form of an emulsion. With either method, the matrix-porosigen, emulsion is added to an excess aqueous solution containing ssurfactant such as poly(vinyl alcohol) with controlled stirring and temperature. The resultant porous particles are hardened by extracting or evaporating residual solvent, and dried.
The porous nature of the particles of the present invention creates sufficient surface area for protein adsorption and increases biodegradation, the desirable extent of both being dependent upon the clinical indication being addressed. Surface area can be measured by any conventional technique. For example, BET surface area analysis can be employed using a Micromeritics ASAP 2000 system as is explained irt'more detail in Examples a and 2 below. The amount of porous particles used to treat a particular defect will, of course, depend upon the size of the defect b'oing treated, and on the effective amount required to_ adsorb the osteogenic protein.
The osteogenic protein-sequestering material useful in the practice of the subject invention is a pharmaceutically acceptable material having a viscosity and polarity such that, when added to an osteogenic protein/porous particle combination, a malleable (putty-like), composite ~is formed that' handles appropriately for surgical implantation into an injury site. Adding the sequestering agent to the combination of bioerodible porous particles plus WO 93/00050 2111,199 PCT/US92/05309 osteogenic protein contains the adsorbed protein within the matrix for a time sufficient to allow the protein to increase the otherwise natural rate of osteogenic activity of the infiltrating mammalian progenitor cells. The sequestering material further allows the osteogenic protein to diffuse from the malleable composite over a time interval appropriate for optimally increasing the rate of osteogenic activity of the progenitor cells. In the absence of such a sequestering material, osteogenic protein desorbs from the PLGA particles in-situ at a rate such that the osteoinducing effect of the protein is not clinically significant.
A preferred family of sequestering agents is cellulosic materials such as alkylcellulose (including hydroxyalkylcellulose), including methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl-methylcellulose, and carboxymethylcellulose, the most preferred being the cationic salts of carboxymethylcellulose (CMC). Other preferred sequestering agents include hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethytene oxide, carboxyvinyl polymer and poly(vinyl alcohol) . The amount of sequestering agent useful herein is 1D.5-20 wto, preferably 1-10 wto based on total formulation weight, which represents the amount necessary to prevent desorbtion of the osteogenic protein from the polymer matrix and to provide apprapriate handling of the cQmposftion, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells.
Additional optional components useful in the practice of the subject application include, e.g. cryogenic protectors such as mannitol, sucrose, lactose, glucose, or glycine (to protect the osteogenic protein from degradation during lyophilization), antimicrobial preservatives such as methyl and propyl parabens and benzyl alcohol; antioxidants' such as EDTA, citrate and BHT
(butylated hydroxytoluene); and surfactants such as poly(sorbates) and poly(oxyethylenes); etc.
According to the present invention, the osteogenic protein is not included in the PLGA polymerization solution or encapsulated in PLGA microcapsules but is added to the already polymerized porous particles. It is preferabl'e to add the porous particles to the solution of osteogenic protein prior to addition of sequestering agent in order to allow the protein to adsorb onto the particles.
Of course, the traditional preparation of formulations in pharmaceutically acceptable form (i.e. pyrogen free, appropriate pH
and isotonicity, sterility, etc.) is well within the skill in the art and is applicable to the formulations of the subject invention.
The formulations may be provided to the clinic as a single vial formulation, either as a solution or in lyophilized form, or the formulation may be provided as a multicomponent kit wherein, e.g.
the osteogenic protein is provided in one vial and the porous particles and sequestering agent are provided in a separate vial or vials.
As seen in Examples 4 and 5 below, the formulations of the subject invention provide malleable implants that allow therapeutically effective amounts of osteoinductive protein to be delivered to an injury site where cartilage and/or bone formation is desired. Such an implant may be used as a substitute for autologous bone graft in fresh and non-union fractures, spinal fusions, and bone defect repair in the orthopaedic field; in cranio/maxillofacial reconstructions, for prosthesis integration, especially as a surface coating; in osteomyelitis for bone regeneration, and in the dental field for erosion of the alveolar ridge and periodontal disease. In certain of these uses, the compositions of the subject invention may be used in combination with various-bone cements, including erodible bone cements such as poly(propylene-co-fumarate). The lower viscosity formulations may also be used as a percutaneous injection to accelerate healing of closed fractures. As alluded to above, the dosage regimen will be determined by the clinicalindication being addressed, as well as by various patient variables (e.g. weight, age, sex) and clinical presentation (e.g. extent of injury, site of injury, etc.), .35 Currently, fresh autogeneic bone is widely used as a bone graft material. The limited supply of autogeneic bone, along with the necessity for an additional harvesting surgical procedure, constitute major disadvantages in use of autogeneic bone for bone grafting. In accordance with the present invention, the porous particles of the invention may be added to autogeneic bone to extend the amount of material available for bone grafting. The porous particles may also be used in combination with a sequestering agent as a substitute for bone wax at the site of a bony injury to act as a bioerodible hemostat.
EXAMPLES
All components utilized in these examples are pharmaceutical grade. The polymeric particle component was made from a 50:50 (molar) random copolymer of lactic acid and glycolic acid (PLGA) having a weight average molecular weight of 30, 000-50, 000, a number average molecular weight of about 20,000 (by gel permeation chromatography relative to polystyrene standards), and an inherent viscosity of 0.35-0.45 dL/g. The osteogenic protein utilized was rBMP-2. The production and characterization of rBMP-2 is described in detail in the above-referenced US 5,013,649. The sequestering agents- utilized included carboxymethyl-cellulose, hydroxy-propylmethyl cellulose, sodium alginate, hyaluronic acid, and poly(ethylene glycol). The carboxysmgthylcellulose (CMC) utilized contained 0.7 degree of substitution (carboxymethyl groups per hydroxy group on cellulose and had a viscosity of 2480 cps.
EXAMPLE 1- PREPARATION Of POROUS PARTICLES
BY SOLVENT E V~P(RATJON TECHNIOUE
PLGA was dissolved in CH2C12 (15% w/v), and 10 g porosigen (7.5% w/v) was suspended in this solution. The resulting solution was added to an excess poly(vinyl alcohol) aqueous solution (0.1%
w/v). After a few hours of stirring under partial vacuum (24 inches Hg), the particles were hardened in excess cold ethanol (950). The resulting particles were washed with water for x._ . ., ,.. .. t; - - .. ,. ,., , .,;~ ...,,.. ... .... ~.. . .. .. ..
WO 93/00050 2111199 E'CT/t.1S92/05309 injection and vacuum dried to give a free-flowing product. BET
surface area analysis was performed using a Micrometrics ASAP 2000 system. The measurement of surface area is based upon adsorption and desorption of Krypton gas at the surface and within the pores of the solid sample. The unit calculates and prints out the surface area:
1 = C-1 (P/Po) + ..~.._ VA L( po/ F' )-1 ] VmC VmC
V = volume absorb at pressure P Po = saturation pressure P/Po = relative pressure P pressure C constant A gas cross secti,onal area Vm = Monolayer Capacity By plotting 1 vs P/P0), the slope being VA ( (Pa/P) -1 C-1 and the intercept being 1 the surface area VmC Vo,C
St = VNA where N = Avogadro's number and V = molar volume.
V
Reactant details and results are depicted in Table 1 and Table 2, respectively.
WO 93/00050 21 t I t 99 i'C:T/uS92/05309 Table 1 Batch PLGA CH2CL2 Porosigen PVA Impellers Stirring No. (grams) (mL) (type/%) mL (ton/btm)_ (rpm) 1 10 67 NaC1/50 1200 (2rshtn/A-100) 215 2 10 67 NaC1/80 1200 (2rshtn/A-100) 215 3 6.7 67 suc/50 1200 (2rshtn/A-100) 215 4 6.7 67 NaC1/50 1200 (2rshtn/A-100) 235 5 16 106 suc/50 2000 (A-310/A-310) 140 6 20 133 suc/50 2000 (A-310/A310) 140 7 20 133 suc/50 2000 (A-310/A-310) 140 8 20 133 suc~:/50 2000 (8.5rsh/A-310) 100 9 20 133 suc/50 2000 (8.5rsh/A-310) 140 10 20 133 suc/50 2000 (2rshtn/A-100) 140 Table =2 Batch Surface Area Yield % Density No. Mn Mw Dp (mZ/q) 250-710um _(ctms/cc) 1 17500 30800 1.75 0.54 27.3 0.41 2 19400 31700 1.64 0.037 71.6 0.67 3 19700 40900 2.07 0.089 92.7 0.70 4 20300 37700 1.86 0.28 69.5 0.37 5 20400 32600 1.60 0.035 N/A N/A
6 20200 37700 1.86 0.079 79.5 0.64 7 0.060 85 0.76 8 0.038 85 0.86 9 0.057 65 0.71 10 20200 37700 1.86 0.060 64 0.68 WO 93/00050 2 1111W PC,"T'/US92/05309 BY SOLVENT EXTRAtTION TECHKIQUE
A 100-g sample of PLGA was dissolved in 670 mL of CH2C12.
The porosigen solution was prepared by dissolving 5g NaC1 in 50 mL of a 0.2% aqueous solution of poly(vinyl alcohol). A 50-mL
aliquot of the porosigen solution was added to a homogenizer and agitated at 3300 rpm. The PLGA solution was then added to the homogenizer (with agitation). A 77 mM NaCI solution in 10 liter of 0.2% aqueous poly(vinyl alcohol) was added to a 12-liter reactor and agitated at 175 rpm. The PLGA/porosigen suspension was added to the reactor over 90 minutes. A 77 mM NaC1 solution in 0.2% aqueous poly(vinyl alcohol) was then pumped into and out of the 12-liter reactor, thereby extracting methylene chloride from the mixture. After solvent extraction was complete, agitation was stopped, the porous particles are allowed to settle, the supernatant was decanted, and the particles were hardened with ethanol (95%) followed by washing with water or a.
solution of polysorbate 20 (0.05%) in water. The washed particles were dried by vacuum or convection techniques. ~
Particles prepared according to this procedure typically have 0.09 g/cc bulk density, and total surface area = 4 m2/g. The dried particles can be sterilized by ethylene oxide exposure or ry irradiation. As noted above, the ~'rad,iation dose influences bioerosion rate. Table 3 gives examples of porous particles prepared by the above process.
.:.... .. . .. . .... . .....,.. . . .. . ... I1 Table 3 Batch Homogenizer Porosigen Soln, Density Yield %
No. (rpm) (mL) ,(C/cc)150-500 Um 1 10,000 50 0.09 80 2 3,500 50 0.15 80 3 6,000 50 0.09 95 4 3,000 50 0.10 95 5 1,900 50 0.29 90 6 2,200 50 0.10 95 7 2,000 50 0.09 99 8 2,000 25 0.14 90 9 2,000 12.5 0.24 90 10 2,000 20 0.28 <75 11 2,000 20 0.18 >75 12 2,000 17.5 0.16 95 13 2,000 15.5 0.21 94 14 2,500 15.5 0.17 90 a ,.
In another embodiment, the subject invention provides a composition comprising polymeric particles having a spherical diameter of between about 150 and 850 microns and a porosity such that the surface area of the particles is between about 0.02 and 4 m2/g, wherein the polymer is selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid; optionally in admixture with osteogenic protein.
In yet another embodiment, the subject invention provides a composition comprising a pharmaceutically acceptable admixture of osteogenic protein and an effective solubilizing amount of a member selected from the group consisting of arginine, histidine, dextran sulfate, gamma-amino butyric acid, beta-amino propionic acid, glycine-glycine, glycine ethyl ester, histidine ethyl ester, lysine methyl ester, arginine methyl este'r; guanidine, 'sodium chloride, heparin, lysine, beta-alanine ethyl ester and agmatine.
DETAILED DESCRIPTION OF THE INVENTION
The osteogenic.proteins useful in the practice of the subject invention are well known to those skilled in the art and include those discussed above. The preferred osteogenic proteins for use herein are those of the BMP class identified as BMP-1 through BMP-8 in U.S. 4,877,864; U.S. 5,0131649; WO 90 , /11366 published October 4, 1990; and WO 91/18098 published November 28, 1991. The most preferred is BMP-2, the mature protein sequence beginning with the ~i... ,. . .. _ . . . _ , ..., ... ., ri. . .. ..... ...... . . r . . . ., .,..1A., ";. ,...i ,.5.... .... ... . . ...., _.. . , . - .... .
-amino acid Gln at nucleotide 1202 and ending with the amino acid Arg at nucleotide 1543, as described in detail in the '649 patent.
Of course, combinations of two or more of such osteogeriic proteins may be used, as may fragments of such proteins that also exhibit osteogenic activity and heterodimeric forms of such proteins.
Recombinant proteins are preferred over naturally occurring isolated proteins. The amount of osteogenic protein useful herein is that amount effective to stimulate increased osteogenic activity of infiltrating progenitor cells, and will depend upon the size and nature of the defect being treated as discussed in more detail below, such amounts being orders of magnitude less than the amount of polymer matrix employed, preferably in the range of 1-50 g of protein for each 10 mg of polymer matrix employed and more preferably in the range of 0.5 - 5 g protein for each mg of polymer matrix employed.
The osteogenic proteins,can be utilized in the form of a pharmaceutically acceptable solution or in lyophilized form. In either case it is optimal to stabilize and solubilize the osteogenic protein, preferably at concentrations of at 'least 1 mg/mi so that a pharmaceutically effective.amount of protein can be delivered without undue volumes of carrier solution being necessary. However, a problem exists in that osteogenic proteins, particularly those of the BMP fami2yy have proven to be difficult to solubilize. As detailed in the examples below, it has been discovered that amino acids having a net positive charge (e.g."net 1+ species such as arginine, histidine, lysine and the ethyl esters of glycine and beta-alanine), preferably a net 2+ charge (e.g. the ethyl ester of histidine, the methyl esters of lysine and arginine, and agmatine) , are useful in this regard. Amino acids having a net zero charge are useful in this regard provided that the positive charge of the compound is sufficiently distant (at least 2-3 CH2 units away) from the"neutralizing negative charge (e.g. net neutral species such as gamma-amino butyric acid, beta-amino propionic acid and glycine-glycine dipeptide). Other solubilizing agents useful WO 93/00050 2111199 PC.'i /US92/0530g herein include dextran sulfate, guanidine, heparin and sodium chloride. For use in solubilizing BMP-2, the preferred solubilizing agents are arginine and histidine (including esters thereof). Arginine is used in concentrations of about 50-600 mM, preferably 300-500 mM. Histidine may be added to arginine to solubilize BMP-2, in concentrations of about 1-100 mM, preferably 10-50 mM. When histidine is used alone as a solubilizing agent, it is used in concentrations of about 50-600'mM, preferably 300-500 mM. Various well known methods may be used to compound the osteogenic protein and solubilizing agents for use herein, including but not limited to ultrafiltration, dialysis, gel filtration, and hydrophobic interaction chromatography.
The polymer matrix component useful in the practice of the subject invention is a polymeric material that can be formed into porous particles as described below thereby providing in-situ scaffolding for the osteogenic protein, while having biodegradable properties allowing for replacement by new bone growth. Examples are aol=1rmers of amino acids, orthoesters, anhydrides, propylene-cou-fumarates, or a polymer of one or more a-hydroxy carboxylic acid monomers, e.g. a-hydroxy acetic acid (glycolic acid) and/or a-hydroxy propionic acid (lactic acid). The latter can be employed in its d- or 1- form, or as a racemic mixture, the racemic mixture being preferred. When a copolymer tSf-lactic acid,and glycolic acid is employed (PLGA), the molar ratio of monomers can range from 1:99 to 99:1 depending upon the desired bioerosion lifetime which in turn depends upon the clinical indication being addressed, as more than 50% of either monomer gives longer bioerosion lifetime (slower biodegradation). The molecular weight of the polymer can range from about 1, 000 to 100,000 with 30, 000-50, 000 being preferred when a 50:50 copolymer is employed. The higher the molecular weight the slower the biodegradation.
The polymeri.c'matrix component of the subject invention is used in the form of highly porous to hollow (with surface porosity) particles, hereinafter collectively referred to as "porous particles." These porous particles are generally spherical having diameters of 150 to 850 microns. This particle size creates sufficient spacing between particles to allow mammalian osteoprogenitor cells to infiltrate and be positively influenced by the osteogenic protein (evidenced by an increase in osteogenic activity/bone growth rate).
While it has generally been postulated that particles suitable as matrices for delivery of osteogenic proteins should be porous, the extent of porosity necessary to optimally induce bone formation has not previously been studied. The present inventors have discovered that the average surface area per porous particle is critical to optimize bone formation. Specifically, porous particles useful in bone formation according to the present invention should have an average surface area of from about 0.02 to 4 m2/g. The present inventors have further discovered that it is possible to produce porous particles having the desired surface area by introducing a "porosigen" (composition capable of imparting porosity by increasing particle surface area) into the solution used to produce the porous particles. It is also possible to control the bioerosion rate by subjecting the porous partit:les to sterilizing doses of y radiation. The higher the 7 radiation dose, the faster the bioerosion.
The method of producing porous particles in accordance with the subject invention and discttssed hereinbelow results in particles having a porosity such that the surface area of the particles is increased about 2-250 fold over the surface area of non-porous particles of comparable size. More specifically, e.g., non-porous PLGA particles having an average size of 400 m have a surface area of 0.018 m2/g. In contrast, PLGA particles useful in the subject invention made utilizing 50% NaCl as a porosigen have a surface area of between about 0.2 and 0.6 mZ/g; and particles made using sucrose as a porosigen have a surface area of between about 0.04 and 0.09 m2/g as 'described! in Example 1. PLGA particles' of the present invention made using liquid porosigen with homogenization as described in Example 2 have a surface area of between about 0.02 . .. .. . .., ,...
= :
..:,.,.x...:, .-., ,-:...rr.,,. ... -:...F . . .,.., . . _-..__. . ......... ..............,......,. .. .,;- . ..,...._. , , ,-. .
. . =. . . a. .,.: ,.,. ..:.., ...=,.....,,. .. _ ... .. , T .
~, . . , ,,. , _.... ,.
and 4 mz/g.
A preferred method of production of the porous particles of the invention is, generally speaking, a solvent evaporation process comprising dissolving the polymer (in e.g. CH2C12), and adding a porosigen such as NaCI, mannitol or sucrose in solid and/or liquid form. When porosigen is added in solid form, the matrix-porosigen solution takes the form of a suspension. Another preferred method of production of the porous particles of the invention is a solvent extraction method, wherein the porosigen is added in liquid form with concomitant homogenization. When porosigen is added in liquid form with homogenization, the matrix-porosigen solution takes the form of an emulsion. With either method, the matrix-porosigen, emulsion is added to an excess aqueous solution containing ssurfactant such as poly(vinyl alcohol) with controlled stirring and temperature. The resultant porous particles are hardened by extracting or evaporating residual solvent, and dried.
The porous nature of the particles of the present invention creates sufficient surface area for protein adsorption and increases biodegradation, the desirable extent of both being dependent upon the clinical indication being addressed. Surface area can be measured by any conventional technique. For example, BET surface area analysis can be employed using a Micromeritics ASAP 2000 system as is explained irt'more detail in Examples a and 2 below. The amount of porous particles used to treat a particular defect will, of course, depend upon the size of the defect b'oing treated, and on the effective amount required to_ adsorb the osteogenic protein.
The osteogenic protein-sequestering material useful in the practice of the subject invention is a pharmaceutically acceptable material having a viscosity and polarity such that, when added to an osteogenic protein/porous particle combination, a malleable (putty-like), composite ~is formed that' handles appropriately for surgical implantation into an injury site. Adding the sequestering agent to the combination of bioerodible porous particles plus WO 93/00050 2111,199 PCT/US92/05309 osteogenic protein contains the adsorbed protein within the matrix for a time sufficient to allow the protein to increase the otherwise natural rate of osteogenic activity of the infiltrating mammalian progenitor cells. The sequestering material further allows the osteogenic protein to diffuse from the malleable composite over a time interval appropriate for optimally increasing the rate of osteogenic activity of the progenitor cells. In the absence of such a sequestering material, osteogenic protein desorbs from the PLGA particles in-situ at a rate such that the osteoinducing effect of the protein is not clinically significant.
A preferred family of sequestering agents is cellulosic materials such as alkylcellulose (including hydroxyalkylcellulose), including methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl-methylcellulose, and carboxymethylcellulose, the most preferred being the cationic salts of carboxymethylcellulose (CMC). Other preferred sequestering agents include hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethytene oxide, carboxyvinyl polymer and poly(vinyl alcohol) . The amount of sequestering agent useful herein is 1D.5-20 wto, preferably 1-10 wto based on total formulation weight, which represents the amount necessary to prevent desorbtion of the osteogenic protein from the polymer matrix and to provide apprapriate handling of the cQmposftion, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells.
Additional optional components useful in the practice of the subject application include, e.g. cryogenic protectors such as mannitol, sucrose, lactose, glucose, or glycine (to protect the osteogenic protein from degradation during lyophilization), antimicrobial preservatives such as methyl and propyl parabens and benzyl alcohol; antioxidants' such as EDTA, citrate and BHT
(butylated hydroxytoluene); and surfactants such as poly(sorbates) and poly(oxyethylenes); etc.
According to the present invention, the osteogenic protein is not included in the PLGA polymerization solution or encapsulated in PLGA microcapsules but is added to the already polymerized porous particles. It is preferabl'e to add the porous particles to the solution of osteogenic protein prior to addition of sequestering agent in order to allow the protein to adsorb onto the particles.
Of course, the traditional preparation of formulations in pharmaceutically acceptable form (i.e. pyrogen free, appropriate pH
and isotonicity, sterility, etc.) is well within the skill in the art and is applicable to the formulations of the subject invention.
The formulations may be provided to the clinic as a single vial formulation, either as a solution or in lyophilized form, or the formulation may be provided as a multicomponent kit wherein, e.g.
the osteogenic protein is provided in one vial and the porous particles and sequestering agent are provided in a separate vial or vials.
As seen in Examples 4 and 5 below, the formulations of the subject invention provide malleable implants that allow therapeutically effective amounts of osteoinductive protein to be delivered to an injury site where cartilage and/or bone formation is desired. Such an implant may be used as a substitute for autologous bone graft in fresh and non-union fractures, spinal fusions, and bone defect repair in the orthopaedic field; in cranio/maxillofacial reconstructions, for prosthesis integration, especially as a surface coating; in osteomyelitis for bone regeneration, and in the dental field for erosion of the alveolar ridge and periodontal disease. In certain of these uses, the compositions of the subject invention may be used in combination with various-bone cements, including erodible bone cements such as poly(propylene-co-fumarate). The lower viscosity formulations may also be used as a percutaneous injection to accelerate healing of closed fractures. As alluded to above, the dosage regimen will be determined by the clinicalindication being addressed, as well as by various patient variables (e.g. weight, age, sex) and clinical presentation (e.g. extent of injury, site of injury, etc.), .35 Currently, fresh autogeneic bone is widely used as a bone graft material. The limited supply of autogeneic bone, along with the necessity for an additional harvesting surgical procedure, constitute major disadvantages in use of autogeneic bone for bone grafting. In accordance with the present invention, the porous particles of the invention may be added to autogeneic bone to extend the amount of material available for bone grafting. The porous particles may also be used in combination with a sequestering agent as a substitute for bone wax at the site of a bony injury to act as a bioerodible hemostat.
EXAMPLES
All components utilized in these examples are pharmaceutical grade. The polymeric particle component was made from a 50:50 (molar) random copolymer of lactic acid and glycolic acid (PLGA) having a weight average molecular weight of 30, 000-50, 000, a number average molecular weight of about 20,000 (by gel permeation chromatography relative to polystyrene standards), and an inherent viscosity of 0.35-0.45 dL/g. The osteogenic protein utilized was rBMP-2. The production and characterization of rBMP-2 is described in detail in the above-referenced US 5,013,649. The sequestering agents- utilized included carboxymethyl-cellulose, hydroxy-propylmethyl cellulose, sodium alginate, hyaluronic acid, and poly(ethylene glycol). The carboxysmgthylcellulose (CMC) utilized contained 0.7 degree of substitution (carboxymethyl groups per hydroxy group on cellulose and had a viscosity of 2480 cps.
EXAMPLE 1- PREPARATION Of POROUS PARTICLES
BY SOLVENT E V~P(RATJON TECHNIOUE
PLGA was dissolved in CH2C12 (15% w/v), and 10 g porosigen (7.5% w/v) was suspended in this solution. The resulting solution was added to an excess poly(vinyl alcohol) aqueous solution (0.1%
w/v). After a few hours of stirring under partial vacuum (24 inches Hg), the particles were hardened in excess cold ethanol (950). The resulting particles were washed with water for x._ . ., ,.. .. t; - - .. ,. ,., , .,;~ ...,,.. ... .... ~.. . .. .. ..
WO 93/00050 2111199 E'CT/t.1S92/05309 injection and vacuum dried to give a free-flowing product. BET
surface area analysis was performed using a Micrometrics ASAP 2000 system. The measurement of surface area is based upon adsorption and desorption of Krypton gas at the surface and within the pores of the solid sample. The unit calculates and prints out the surface area:
1 = C-1 (P/Po) + ..~.._ VA L( po/ F' )-1 ] VmC VmC
V = volume absorb at pressure P Po = saturation pressure P/Po = relative pressure P pressure C constant A gas cross secti,onal area Vm = Monolayer Capacity By plotting 1 vs P/P0), the slope being VA ( (Pa/P) -1 C-1 and the intercept being 1 the surface area VmC Vo,C
St = VNA where N = Avogadro's number and V = molar volume.
V
Reactant details and results are depicted in Table 1 and Table 2, respectively.
WO 93/00050 21 t I t 99 i'C:T/uS92/05309 Table 1 Batch PLGA CH2CL2 Porosigen PVA Impellers Stirring No. (grams) (mL) (type/%) mL (ton/btm)_ (rpm) 1 10 67 NaC1/50 1200 (2rshtn/A-100) 215 2 10 67 NaC1/80 1200 (2rshtn/A-100) 215 3 6.7 67 suc/50 1200 (2rshtn/A-100) 215 4 6.7 67 NaC1/50 1200 (2rshtn/A-100) 235 5 16 106 suc/50 2000 (A-310/A-310) 140 6 20 133 suc/50 2000 (A-310/A310) 140 7 20 133 suc/50 2000 (A-310/A-310) 140 8 20 133 suc~:/50 2000 (8.5rsh/A-310) 100 9 20 133 suc/50 2000 (8.5rsh/A-310) 140 10 20 133 suc/50 2000 (2rshtn/A-100) 140 Table =2 Batch Surface Area Yield % Density No. Mn Mw Dp (mZ/q) 250-710um _(ctms/cc) 1 17500 30800 1.75 0.54 27.3 0.41 2 19400 31700 1.64 0.037 71.6 0.67 3 19700 40900 2.07 0.089 92.7 0.70 4 20300 37700 1.86 0.28 69.5 0.37 5 20400 32600 1.60 0.035 N/A N/A
6 20200 37700 1.86 0.079 79.5 0.64 7 0.060 85 0.76 8 0.038 85 0.86 9 0.057 65 0.71 10 20200 37700 1.86 0.060 64 0.68 WO 93/00050 2 1111W PC,"T'/US92/05309 BY SOLVENT EXTRAtTION TECHKIQUE
A 100-g sample of PLGA was dissolved in 670 mL of CH2C12.
The porosigen solution was prepared by dissolving 5g NaC1 in 50 mL of a 0.2% aqueous solution of poly(vinyl alcohol). A 50-mL
aliquot of the porosigen solution was added to a homogenizer and agitated at 3300 rpm. The PLGA solution was then added to the homogenizer (with agitation). A 77 mM NaCI solution in 10 liter of 0.2% aqueous poly(vinyl alcohol) was added to a 12-liter reactor and agitated at 175 rpm. The PLGA/porosigen suspension was added to the reactor over 90 minutes. A 77 mM NaC1 solution in 0.2% aqueous poly(vinyl alcohol) was then pumped into and out of the 12-liter reactor, thereby extracting methylene chloride from the mixture. After solvent extraction was complete, agitation was stopped, the porous particles are allowed to settle, the supernatant was decanted, and the particles were hardened with ethanol (95%) followed by washing with water or a.
solution of polysorbate 20 (0.05%) in water. The washed particles were dried by vacuum or convection techniques. ~
Particles prepared according to this procedure typically have 0.09 g/cc bulk density, and total surface area = 4 m2/g. The dried particles can be sterilized by ethylene oxide exposure or ry irradiation. As noted above, the ~'rad,iation dose influences bioerosion rate. Table 3 gives examples of porous particles prepared by the above process.
.:.... .. . .. . .... . .....,.. . . .. . ... I1 Table 3 Batch Homogenizer Porosigen Soln, Density Yield %
No. (rpm) (mL) ,(C/cc)150-500 Um 1 10,000 50 0.09 80 2 3,500 50 0.15 80 3 6,000 50 0.09 95 4 3,000 50 0.10 95 5 1,900 50 0.29 90 6 2,200 50 0.10 95 7 2,000 50 0.09 99 8 2,000 25 0.14 90 9 2,000 12.5 0.24 90 10 2,000 20 0.28 <75 11 2,000 20 0.18 >75 12 2,000 17.5 0.16 95 13 2,000 15.5 0.21 94 14 2,500 15.5 0.17 90 a ,.
15 2,200 15.5 0.19 90 WO 93/00050 2111199 PC";f/US92/05309 Solubility of rBMP-2 in the excipients listed in Table 4 below was determined by dialysis in accordance with the following. Concentrations were determined by absorbencies at 280 nm using an extinction coefficient of 1.62. Protein solution (1 ml) containing 2-3 mg/ml of protein, 0.5M arginine and 10mM
phosphate (pH 6.5) was dialyzed against 1000 ml of buffer containing 0.5M excipient of choice (see Table 3) and 0.5M
arginine, pH 6.5. The dialysis was carried out at room temperature. The excipients were allowed to equilibrate with the protein solution. The protein solution was then dialyzed twice against 1000 ml of an arginine-less buffer solution of otherwise identical composition. Solubility results are presented in Table 4. Unless otherwise indicated, excipients were tested at standard concentrations of 500mM.
phosphate (pH 6.5) was dialyzed against 1000 ml of buffer containing 0.5M excipient of choice (see Table 3) and 0.5M
arginine, pH 6.5. The dialysis was carried out at room temperature. The excipients were allowed to equilibrate with the protein solution. The protein solution was then dialyzed twice against 1000 ml of an arginine-less buffer solution of otherwise identical composition. Solubility results are presented in Table 4. Unless otherwise indicated, excipients were tested at standard concentrations of 500mM.
Table 4 NET CHARGE SOLUBILITY
EXCIPIENT (at neutral pH) (mg/m1) E-amino caproic acid 0 <0.4 6-amino valeric acid 0 <0.4 7-amino butyric acid 0 >1.7 0-amino propionic acid 0 >1=1 Glycine-Glycine dipeptide 0 2:1.8 Glycine 0 <_0=4 Arginine 1+ >5.4 Lysine 1+ >0.9 Guanidine 1+ >1.8 Glycine (ethyl ester) 1+ 22.2 Histidine (ethyl ester) 2+ >2.2 Lysine (methyl ester) 2+ >2..2 Arginine (methyl ester) 2+ >2=2 Histidine 1+ >2.2 Dextran sulfate 2:1 = 7 1.OM NaCl 0 >1.8 WO 93/00050 PC7 /t1S92/05309 rBMP-2 (22 pg), mannitol (8 mg), and epsilon aminocaproic acid (2M, 20 l) were lyophilized onto the PLGA particles (10 mg, 20% porosity, 325 mm). CMC (5.5 mg, -9%) was added and the solid powder was sterilized using ethylene oxide. Water for Injection (60 l) was added to form a malleable implant of the composite.
As a control, the same formulation was made without the CMC, in which case a gelatin capsule was used to hold the formulation in place. Both formulations were implanted in a 5 mm rat femur defect. The rats were sacrificed after twelve weeks. Ex-vivo analysis of the new bone was performed radiographically relative to the contralateral femur. Surprisingly, 83% (10 of 12) of the femur defects showed union utilizing the formulations of the subject invention, compared with only 50% (4 of 8) for the control.
A 300- L aliquot of 0.12 ang/mL rBMP2 solution (in 0.25 M
arginine, 10 mM histidine, pH 6.5, plus 20 mM calcium chloride) was added to 9.6 mg of porous particles (0.16 g/cc density, surface area = approximately 0.8 m2/g, sterilized by 2.5 Mrad ry radiation). To this mixture was added 15 mg sodium alginate.
Gentle mixing provided a mal-leable composite. Similar formulations were made using 9 mg of hydroxypropylmethylcellulose or 9 mg carboxymethylcellulose except that the 0.12 mg/mL rBMP2 was solubilized in 0.25 M arginine plus 10 mM histidine, pH 6.5 (no added calcium chloride). As controls, malleable formulations WO 93/00050 2111199 PC'r/US92/05309 were prepared with 0.25 M arginine plus 10mM histidine containing 0 mg/mL rBMP2. The formulations were implanted into 8 mm diameter critical size circular defects in rat calvarium. After 21 days the animals were sacrificed and bone regeneration assessed by radiomorphometry (X-OMATL high contrast X-ray film, using Cambridge 520 Image Analysis System); The control samples for alginate, CMC, and hydroxypropylmethyl-cellulose formulations, respectively, showed only 18%, 10% and 10%, radiopacity. By comparison the alginate, CMC and hydroxypropylmethylcellulose formulations (with added rBMP2) showed, respectively, 72%, 70% and 67% radiopacity indicating significant new bone growth.
EXCIPIENT (at neutral pH) (mg/m1) E-amino caproic acid 0 <0.4 6-amino valeric acid 0 <0.4 7-amino butyric acid 0 >1.7 0-amino propionic acid 0 >1=1 Glycine-Glycine dipeptide 0 2:1.8 Glycine 0 <_0=4 Arginine 1+ >5.4 Lysine 1+ >0.9 Guanidine 1+ >1.8 Glycine (ethyl ester) 1+ 22.2 Histidine (ethyl ester) 2+ >2.2 Lysine (methyl ester) 2+ >2..2 Arginine (methyl ester) 2+ >2=2 Histidine 1+ >2.2 Dextran sulfate 2:1 = 7 1.OM NaCl 0 >1.8 WO 93/00050 PC7 /t1S92/05309 rBMP-2 (22 pg), mannitol (8 mg), and epsilon aminocaproic acid (2M, 20 l) were lyophilized onto the PLGA particles (10 mg, 20% porosity, 325 mm). CMC (5.5 mg, -9%) was added and the solid powder was sterilized using ethylene oxide. Water for Injection (60 l) was added to form a malleable implant of the composite.
As a control, the same formulation was made without the CMC, in which case a gelatin capsule was used to hold the formulation in place. Both formulations were implanted in a 5 mm rat femur defect. The rats were sacrificed after twelve weeks. Ex-vivo analysis of the new bone was performed radiographically relative to the contralateral femur. Surprisingly, 83% (10 of 12) of the femur defects showed union utilizing the formulations of the subject invention, compared with only 50% (4 of 8) for the control.
A 300- L aliquot of 0.12 ang/mL rBMP2 solution (in 0.25 M
arginine, 10 mM histidine, pH 6.5, plus 20 mM calcium chloride) was added to 9.6 mg of porous particles (0.16 g/cc density, surface area = approximately 0.8 m2/g, sterilized by 2.5 Mrad ry radiation). To this mixture was added 15 mg sodium alginate.
Gentle mixing provided a mal-leable composite. Similar formulations were made using 9 mg of hydroxypropylmethylcellulose or 9 mg carboxymethylcellulose except that the 0.12 mg/mL rBMP2 was solubilized in 0.25 M arginine plus 10 mM histidine, pH 6.5 (no added calcium chloride). As controls, malleable formulations WO 93/00050 2111199 PC'r/US92/05309 were prepared with 0.25 M arginine plus 10mM histidine containing 0 mg/mL rBMP2. The formulations were implanted into 8 mm diameter critical size circular defects in rat calvarium. After 21 days the animals were sacrificed and bone regeneration assessed by radiomorphometry (X-OMATL high contrast X-ray film, using Cambridge 520 Image Analysis System); The control samples for alginate, CMC, and hydroxypropylmethyl-cellulose formulations, respectively, showed only 18%, 10% and 10%, radiopacity. By comparison the alginate, CMC and hydroxypropylmethylcellulose formulations (with added rBMP2) showed, respectively, 72%, 70% and 67% radiopacity indicating significant new bone growth.
aacem:.z:.r...- ,:--:::.: ...:..;_..... . .;...-.... -... ..._ ... .___:S S i7 ,
Claims (40)
1. A composition comprising a pharmaceutically acceptable admixture of (i) an osteogenic protein that is not encapsulated in a microcapsule;
(ii) a polymer matrix component selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid; and (iii)approximately 0.5 - 20 wt % osteogenic protein-sequestering alkylcellulose, based on the total composition weight.
(ii) a polymer matrix component selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid; and (iii)approximately 0.5 - 20 wt % osteogenic protein-sequestering alkylcellulose, based on the total composition weight.
2. The composition of claim 1 wherein the osteogenic protein is selected from the group consisting of the members of the BMP-family.
3. The composition of claim 2 wherein the osteogenic protein is BMP-2.
4. The composition of claim 2 wherein the cellulosic material is selected from hydroxypropylmethylcellulose and carboxymethylcellulose.
5. The composition of claim 3 wherein the cellulosic material is selected from hydroxypropylmethylcellulose and carboxymethylcellulose.
6. The composition of claim 5, wherein the polymer matrix component is a copolymer of lactic acid and glycolic acid.
7. The composition of claim 1 wherein the polymer matrix component is in the form of porous particles.
8. The composition of claim 2 wherein the polymer matrix component is in the form of porous particles.
9. The composition of claim 3 wherein the polymer matrix component is in the form of porous particles.
10. The composition of claim 4 wherein the polymer matrix component is in the form of porous particles.
11. The composition of claim 5 wherein the polymer matrix component is in the form of porous particles.
12. The composition of claim 6 wherein the polymer matrix component is in the form of porous particles.
13. A composition comprising a pharmaceutically acceptable admixture of (i) BMP-2 that is not encapsulated in a microcapsule;
(ii) a porous polymeric matrix component comprising polymeric particles having a diameter of between about 150 and 850 microns and a porosity such that the surface area of the particles is between about 0.02 and 4m2/g, wherein the polymer is selected from the group consisting of poly(lactic acid), poly(glycolic acid) and copolymers of lactic acid and glycolic acid; and (iii) approximately 0.5 - 20 wt % protein-sequestering amount of carboxymethylcellulose, based on the total composition weight.
(ii) a porous polymeric matrix component comprising polymeric particles having a diameter of between about 150 and 850 microns and a porosity such that the surface area of the particles is between about 0.02 and 4m2/g, wherein the polymer is selected from the group consisting of poly(lactic acid), poly(glycolic acid) and copolymers of lactic acid and glycolic acid; and (iii) approximately 0.5 - 20 wt % protein-sequestering amount of carboxymethylcellulose, based on the total composition weight.
14. The composition of claim 1 wherein the osteogenic protein is TGF-.beta..
15. The composition of claim 1 wherein the osteogenic protein is Vgr-1.
16. The composition of claim 1 wherein the osteogenic protein is OP-1.
17. The composition of claim 1 wherein the osteogenic protein is selected from COP-5 and COP-7.
18. A composition comprising:
(i) an osteogenic protein that is not encapsulated in a microcapsule;
(ii) porous polymeric particles having a spherical diameter of between about 150 and 850 microns and a porosity such that the surface area of the particles is between about 0.02 and 4m2/g, wherein the polymer is selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid; and (iii) a protein sequestering amount of carboxymethylcellulose.
(i) an osteogenic protein that is not encapsulated in a microcapsule;
(ii) porous polymeric particles having a spherical diameter of between about 150 and 850 microns and a porosity such that the surface area of the particles is between about 0.02 and 4m2/g, wherein the polymer is selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid; and (iii) a protein sequestering amount of carboxymethylcellulose.
19. A composition comprising a pharmaceutically acceptable admixture of osteogenic protein that is not encapsulated in a microcapsule, and an effective solubilizing amount of a member selected from the group consisting of arginine, histidine, dextran sulfate, gamma-amino butyric acid, beta-amino propionic acid, glycine-glycine, glycine ethyl ester, histidine ethyl ester, lysine methyl ester, arginine methyl ester, guanidine, sodium chloride, heparin, lysine, beta-alanine ethyl ester and agmatine;
and a porous polymer matrix component selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid.
and a porous polymer matrix component selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid.
20. A composition comprising a pharmaceutically acceptable admixture of (i) an osteogenic protein that is not encapsulated in a microcapsule;
(ii) a porous polymer matrix component selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid; and (iii) approximately 0.5 - 20 wt % osteogenic protein-sequestering agent selected from the group consisting of hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer, and poly(vinyl alcohol), based on the total composition weight.
(ii) a porous polymer matrix component selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid; and (iii) approximately 0.5 - 20 wt % osteogenic protein-sequestering agent selected from the group consisting of hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer, and poly(vinyl alcohol), based on the total composition weight.
21. A use of a composition comprising a pharmaceutically acceptable admixture of (i) an osteogenic protein that is not encapsulated in a microcapsule;
(ii) a porous polymer matrix component selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid; and (iii) approximately 0.5 - 20 wt % osteogenic protein-sequestering alkylcellulose, based on the total composition weight;
to sequester osteogenic proteins in situ for a time sufficient to allow the protein to induce cartilage and/or bone formation.
(ii) a porous polymer matrix component selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid; and (iii) approximately 0.5 - 20 wt % osteogenic protein-sequestering alkylcellulose, based on the total composition weight;
to sequester osteogenic proteins in situ for a time sufficient to allow the protein to induce cartilage and/or bone formation.
22. A use of a composition comprising a pharmaceutically acceptable admixture of (i) an osteogenic protein that is not encapsulated in a microcapsule;
(ii) a porous polymer matrix component selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid; and (iii) approximately 0.5 - 20 wt % osteogenic protein-sequestering alkylcellulose, based on the total composition weight;
for the production of a medicament to sequester osteogenic proteins in situ for a time sufficient to allow the protein to induce cartilage and/or bone formation.
(ii) a porous polymer matrix component selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid; and (iii) approximately 0.5 - 20 wt % osteogenic protein-sequestering alkylcellulose, based on the total composition weight;
for the production of a medicament to sequester osteogenic proteins in situ for a time sufficient to allow the protein to induce cartilage and/or bone formation.
23. A use of a composition comprising a pharmaceutically acceptable admixture of (i) BMP-2 that is not encapsulated in a microcapsule;
(ii) a porous polymeric matrix component comprising polymeric particles having a diameter of between about 150 and 850 microns and a porosity such that the surface area of the particles is between about 0.02 and 4 m2/g, wherein the polymer is selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid; and (iii) approximately 0.5 - 20 wt % protein-sequestering amount of carboxymethylcellulose, based on the total composition weight;
to sequester osteogenic proteins in situ for a time sufficient to allow the protein to induce cartilage and/or bone formation.
(ii) a porous polymeric matrix component comprising polymeric particles having a diameter of between about 150 and 850 microns and a porosity such that the surface area of the particles is between about 0.02 and 4 m2/g, wherein the polymer is selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid; and (iii) approximately 0.5 - 20 wt % protein-sequestering amount of carboxymethylcellulose, based on the total composition weight;
to sequester osteogenic proteins in situ for a time sufficient to allow the protein to induce cartilage and/or bone formation.
24. A use of a composition comprising a pharmaceutically acceptable admixture of (i) BMP-2 that is not encapsulated in a microcapsule;
(ii) a porous polymeric matrix component comprising polymeric particles having a diameter of between about 150 and 850 microns and a porosity such that the surface area of the particles is between about 0.02 and 4 m2/g, wherein the polymer is selected from the group consisting of poly(lactic acid), poly(glycolic acid); and (iii) approximately 0.5 - 20 wt % protein-sequestering amount of carboxymethylcellulose, based on the total composition weight;
for the production of a medicament to sequester osteogenic proteins in situ for a time sufficient to allow the protein to induce cartilage and/or bone formation.
(ii) a porous polymeric matrix component comprising polymeric particles having a diameter of between about 150 and 850 microns and a porosity such that the surface area of the particles is between about 0.02 and 4 m2/g, wherein the polymer is selected from the group consisting of poly(lactic acid), poly(glycolic acid); and (iii) approximately 0.5 - 20 wt % protein-sequestering amount of carboxymethylcellulose, based on the total composition weight;
for the production of a medicament to sequester osteogenic proteins in situ for a time sufficient to allow the protein to induce cartilage and/or bone formation.
25. A use of a composition comprising:
(i) an osteogenic protein that is not encapsulated in a microcapsule;
(ii) porous polymeric particles having a spherical diameter of between about 150 and 850 microns and a porosity such that the surface area of the particles is between about 0.02 and 4m2/g, wherein the polymer is selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid; and (iii) a protein sequestering amount of carboxymethylcellulose;
to sequester osteogenic proteins in situ for a time sufficient to allow the protein to induce cartilage and/or bone formation.
(i) an osteogenic protein that is not encapsulated in a microcapsule;
(ii) porous polymeric particles having a spherical diameter of between about 150 and 850 microns and a porosity such that the surface area of the particles is between about 0.02 and 4m2/g, wherein the polymer is selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid; and (iii) a protein sequestering amount of carboxymethylcellulose;
to sequester osteogenic proteins in situ for a time sufficient to allow the protein to induce cartilage and/or bone formation.
26. A use of a composition comprising:
(i) an osteogenic protein that is not encapsulated in a microcapsule;
(ii) porous polymeric particles having a spherical diameter of between about 150 and 850 microns and a porosity such that the surface area of the particles is between about 0.02 and 4m2/g, wherein the polymer is selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid; and (iii) a protein sequestering amount of carboxymethylcellulose;
for the production of a medicament to sequester osteogenic proteins in situ for a time sufficient to allow the protein to induce cartilage and/or bone formation.
(i) an osteogenic protein that is not encapsulated in a microcapsule;
(ii) porous polymeric particles having a spherical diameter of between about 150 and 850 microns and a porosity such that the surface area of the particles is between about 0.02 and 4m2/g, wherein the polymer is selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid; and (iii) a protein sequestering amount of carboxymethylcellulose;
for the production of a medicament to sequester osteogenic proteins in situ for a time sufficient to allow the protein to induce cartilage and/or bone formation.
27. A use of a composition comprising a pharmaceutically acceptable admixture of osteogenic protein that is not encapsulated in a microcapsule and an effective solubilizing amount of a member selected from the group consisting of arginine, histidine, dextran sulfate, gamma-amino butyric acid, beta-amino propionic acid, glycine-glycine, glycine ethyl ester, histidine ethyl ester, lysine methyl ester, arginine methyl ester, guanidine, sodium chloride, heparin, lysine, beta-alanine ethyl ester and agmatine; and a porous polymer matrix component selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid;
to sequester osteogenic proteins in situ for a time sufficient to allow the protein to induce cartilage and/or bone formation
to sequester osteogenic proteins in situ for a time sufficient to allow the protein to induce cartilage and/or bone formation
28. A use of a composition comprising a pharmaceutically acceptable admixture of osteogenic Protein that is not encapsulated in a microcapsule, and an effective solubilizing amount of a member selected from the group consisting of arginine, histidine, dextran sulfate, gamma-amino butyric acid, beta-amino propionic acid, glycine-glycine, glycine ethyl ester, histidine ethyl ester, lysine methyl ester, arginine methyl ester, guanidine, sodium chloride, heparin, lysine, beta-alanine ethyl ester and agmatine; and a porous polymer matrix component selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid;
for the production of a medicament to sequester osteogenic proteins in situ for a time sufficient to allow the protein to induce cartilage and/or bone formation.
for the production of a medicament to sequester osteogenic proteins in situ for a time sufficient to allow the protein to induce cartilage and/or bone formation.
29. A use of a composition comprising a pharmaceutically acceptable admixture of (i) an osteogenic protein that is not encapsulated in a microcapsule;
(ii) a porous polymer matrix component selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid; and (iii) approximately 0.5 - 20 wt % osteogenic protein-sequestering agent selected from the group consisting of hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer, and poly(vinyl alcohol), based on the total composition weight;
to sequester osteogenic proteins in situ for a time sufficient to allow the protein to induce cartilage and/or bone formation.
(ii) a porous polymer matrix component selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid; and (iii) approximately 0.5 - 20 wt % osteogenic protein-sequestering agent selected from the group consisting of hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer, and poly(vinyl alcohol), based on the total composition weight;
to sequester osteogenic proteins in situ for a time sufficient to allow the protein to induce cartilage and/or bone formation.
30. A use of a composition comprising a pharmaceutically acceptable admixture of (i) an osteogenic protein that is not encapsulated in a microcapsule;
(ii) a porous polymer matrix component selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid, and wherein the osteogenic protein is not encapsulated within the polymer matrix; and (iii) approximately 0.5 - 20 wt % osteogenic protein-sequestering agent hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer, and poly(vinyl alcohol), based on the total composition weight;
for the production of a medicament to sequester osteogenic proteins in situ for a time sufficient to allow the protein to induce cartilage and/or bone formation.
(ii) a porous polymer matrix component selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid, and wherein the osteogenic protein is not encapsulated within the polymer matrix; and (iii) approximately 0.5 - 20 wt % osteogenic protein-sequestering agent hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer, and poly(vinyl alcohol), based on the total composition weight;
for the production of a medicament to sequester osteogenic proteins in situ for a time sufficient to allow the protein to induce cartilage and/or bone formation.
31. The composition of any one of claims 18 to 20, wherein the osteogenic protein is selected from the group consisting of the members of the BMP-family.
32. The composition of claim 31, wherein the osteogenic protein is BMP-2.
33. The composition of any one of claims 18 to 20, wherein the osteogenic protein is selected from the group consisting of TGF-.beta., Vgr-1, COP-5, COP-7, and OP-1.
34. The composition of any one of claims 31 to 33, wherein the polymer or polymer matrix component is a copolymer of lactic acid and glycolic acid.
35. The use of any one of claims 21, 22, and 25 to 30, wherein the osteogenic protein is selected from the group consisting of the members of the BMP-family.
36. The use of claim 35, wherein the osteogenic protein is BMP-2.
37. The use of any one of claims 21, 22, and 25 to 30, wherein the osteogenic protein is selected from the group consisting of TGF-.beta., Vgr-1, COP-5, COP-7, and OP-1.
38. The use of any one of claims 35 to 37, wherein the polymer or polymer matrix component is a copolymer of lactic acid and glycolic acid.
39. The composition of any one of claims 1 to 20 and 31 to 34, wherein the composition is subjected to gamma radiation for controlling bioerosion of the composition.
40. The use of the composition of any one of claims 21 to 30 and 35 to 38, wherein the composition is subjected to gamma radiation for controlling bioerosion of the composition.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71872191A | 1991-06-21 | 1991-06-21 | |
| US07/718,721 | 1991-06-21 | ||
| PCT/US1992/005309 WO1993000050A1 (en) | 1991-06-21 | 1992-06-22 | Pharmaceutical formulations of osteogenic proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2111199A1 CA2111199A1 (en) | 1993-01-07 |
| CA2111199C true CA2111199C (en) | 2008-08-05 |
Family
ID=24887221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002111199A Expired - Fee Related CA2111199C (en) | 1991-06-21 | 1992-06-22 | Pharmaceutical formulations of osteogenic proteins |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US5597897A (en) |
| EP (1) | EP0591392B1 (en) |
| JP (1) | JP3351525B2 (en) |
| KR (1) | KR0145278B1 (en) |
| AT (1) | ATE142460T1 (en) |
| AU (1) | AU663328B2 (en) |
| CA (1) | CA2111199C (en) |
| DE (1) | DE69213739T2 (en) |
| DK (1) | DK0591392T3 (en) |
| ES (1) | ES2094359T3 (en) |
| FI (1) | FI109274B (en) |
| GR (1) | GR3021627T3 (en) |
| MX (1) | MX9203083A (en) |
| NO (2) | NO934573D0 (en) |
| WO (1) | WO1993000050A1 (en) |
Families Citing this family (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5705485A (en) * | 1987-09-18 | 1998-01-06 | Ethicon, Inc. | Gel formulations containing growth factors |
| US5674844A (en) * | 1991-03-11 | 1997-10-07 | Creative Biomolecules, Inc. | Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases |
| US7056882B2 (en) | 1991-03-11 | 2006-06-06 | Curis, Inc. | Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases |
| US5171579A (en) * | 1991-10-11 | 1992-12-15 | Genetics Institute, Inc. | Formulations of blood clot-polymer matrix for delivery of osteogenic proteins |
| US5385887A (en) * | 1993-09-10 | 1995-01-31 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
| US6027919A (en) | 1993-12-07 | 2000-02-22 | Genetics Institute, Inc. | BMP-12 and BMP-13 proteins and DNA encoding them |
| ATE319823T1 (en) | 1993-12-07 | 2006-03-15 | Inst Genetics Llc | BMP-12, BMP-13 AND TENDON-INDUCING COMPOSITIONS CONTAINING SAME |
| WO1995024210A1 (en) | 1994-03-08 | 1995-09-14 | Genetics Institute, Inc. | Methods and compositions for treatment of periodontal disease and repair of periodontal lesions |
| CA2151547C (en) | 1994-06-10 | 2010-10-12 | Elliott A. Gruskin | Recombinant chimeric proteins and methods of use thereof |
| US5520923A (en) * | 1994-09-19 | 1996-05-28 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
| FR2726571B1 (en) * | 1994-11-03 | 1997-08-08 | Izoret Georges | BIOLOGICAL GLUE, PREPARATION METHOD AND APPLICATION DEVICE FOR BIOLOGICAL GLUE, AND HARDENERS FOR BIOLOGICAL GLUE |
| US20060280774A1 (en) * | 1995-06-02 | 2006-12-14 | Allergan, Inc. | Compositions and methods for treating glaucoma |
| US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| HU222664B1 (en) | 1995-06-05 | 2003-09-29 | Genetics Institute, Llc | Use of bone morphogenetic protein (bmp) for regeneration of functional connection of bone and tendon or ligament |
| US6352972B1 (en) * | 1995-06-06 | 2002-03-05 | Marcel E. Nimni | Bone morphogenetic proteins and their use in bone growth |
| US5674292A (en) | 1995-06-07 | 1997-10-07 | Stryker Corporation | Terminally sterilized osteogenic devices and preparation thereof |
| JPH09143093A (en) * | 1995-11-17 | 1997-06-03 | Hoechst Japan Ltd | Cartilage/bone-inductive restoring material |
| ATE493141T1 (en) | 1996-03-22 | 2011-01-15 | Stryker Corp | METHOD FOR IMPROVED FUNCTIONAL RECOVERY OF MOTOR COORDINATION, LANGUAGE OR SENSORY PERCEPTION AFTER CNS TRAUMA OR ISCHEMIA |
| US5700774A (en) * | 1996-03-26 | 1997-12-23 | Genetics Institute, Inc. | Compositions comprising bone morphogenic proteins and truncated parathyroid hormone related peptide, and methods of inducing cartilage by administration of same |
| US6492508B1 (en) | 1996-06-03 | 2002-12-10 | United States Surgical Corp. A Division Of Tyco Healthcare Group | Nucleic acids encoding extracellular matrix proteins |
| GB9621825D0 (en) * | 1996-10-19 | 1996-12-11 | Andaris Ltd | Microparticles and their use as therapeutic vehicles |
| WO1998031788A1 (en) * | 1997-01-21 | 1998-07-23 | Genetics Institute, Inc. | Injectable formulations for treatment of osteoporotic bone |
| ATE302021T1 (en) * | 1997-01-30 | 2005-09-15 | Bioph Biotech Entw Pharm Gmbh | FREEZE-DRIED COMPOSITION OF HUMAN MORPHOGENIC BONE PROTEIN MP52 |
| US20040132653A1 (en) * | 1997-01-30 | 2004-07-08 | Biopharm Gmbh | Lyophilized composition of bone morphogenetic factor human MP52 |
| US20010016646A1 (en) | 1998-03-20 | 2001-08-23 | David C. Rueger | Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects |
| US7041641B2 (en) | 1997-03-20 | 2006-05-09 | Stryker Corporation | Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects |
| EP0902036A1 (en) | 1997-09-05 | 1999-03-17 | Roche Diagnostics GmbH | Peptide containing an arginine mimetic for the treatment of osteoporosis, their production, and drugs containing these compounds |
| FR2764514B1 (en) | 1997-06-13 | 1999-09-03 | Biopharmex Holding Sa | IMPLANT INJECTED IN SUBCUTANEOUS OR INTRADERMAL WITH CONTROLLED BIORESORBABILITY FOR REPAIR OR PLASTIC SURGERY AND AESTHETIC DERMATOLOGY |
| DE19726412A1 (en) * | 1997-06-21 | 1998-12-24 | Merck Patent Gmbh | Implant material with a carrier-drug combination |
| EP1007673B1 (en) | 1997-07-30 | 2008-12-17 | Emory University | Novel bone mineralization proteins, dna, vectors, expression systems |
| US7923250B2 (en) | 1997-07-30 | 2011-04-12 | Warsaw Orthopedic, Inc. | Methods of expressing LIM mineralization protein in non-osseous cells |
| EP0906759A1 (en) | 1997-10-02 | 1999-04-07 | Roche Diagnostics GmbH | Novel osteoblastic specific mitogenes: process for their preparation and drugs containing these compounds |
| US6911553B1 (en) | 1997-10-02 | 2005-06-28 | Roche Diagnostics Gmbh | Osteoblast-specific mitogens and drugs containing such compounds |
| US6767892B1 (en) * | 1997-11-07 | 2004-07-27 | Chrion Corporation | Compositions providing for increased IGF-I solubility |
| CA2312009A1 (en) | 1997-11-28 | 1999-06-10 | Roche Diagnostics Gmbh | An active hedgehog-protein-mutant, a process for its preparation and its use for pharmaceutical purposes |
| WO1999030632A1 (en) * | 1997-12-18 | 1999-06-24 | Comfort Biomedical, Inc. | Bone augmentation for prosthetic implants and the like |
| US6214049B1 (en) | 1999-01-14 | 2001-04-10 | Comfort Biomedical, Inc. | Method and apparatus for augmentating osteointegration of prosthetic implant devices |
| US20030147860A1 (en) | 2002-02-07 | 2003-08-07 | Marchosky J. Alexander | Compositions and methods for forming and strengthening bone |
| US6849255B2 (en) | 1998-08-18 | 2005-02-01 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods and compositions for enhancing cartilage repair |
| US6630457B1 (en) * | 1998-09-18 | 2003-10-07 | Orthogene Llc | Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same |
| KR20010075476A (en) * | 1998-09-30 | 2001-08-09 | 다케다 야쿠힌 고교 가부시키가이샤 | Bone repair materials/artificial bone compositions |
| US6663870B2 (en) | 1998-12-07 | 2003-12-16 | Zymogenetics, Inc. | Methods for promoting growth of bone using zvegf3 |
| DE19906096A1 (en) | 1999-02-13 | 2000-08-17 | Walter Sebald | Protein with a heparin-binding epitope |
| US6468543B1 (en) | 1999-05-03 | 2002-10-22 | Zymogenetics, Inc. | Methods for promoting growth of bone using ZVEGF4 |
| AU782394B2 (en) | 1999-06-29 | 2005-07-21 | J. Alexander Marchosky | Compositions and methods for forming and strengthening bone |
| AU2000251259A1 (en) * | 2000-02-04 | 2001-08-14 | Zymogenetics Inc. | Methods for promoting growth of bone, ligament, and cartilage using zvegf4 |
| US6726918B1 (en) | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
| DE60121017T2 (en) * | 2000-10-24 | 2007-01-11 | SDGI Holdings, Inc., Wilmington | DEVICE AND METHOD FOR BONE CONSTRUCTION FULL PLUG |
| CA2429998C (en) | 2000-11-29 | 2012-01-17 | Oculex Pharmaceuticals, Inc. | Intraocular implants for preventing transplant rejection in the eye |
| US6949251B2 (en) * | 2001-03-02 | 2005-09-27 | Stryker Corporation | Porous β-tricalcium phosphate granules for regeneration of bone tissue |
| IL158622A0 (en) | 2001-04-30 | 2004-05-12 | Yissum Res Dev Co | Composite scaffolds and methods using same for generating complex tissue grafts |
| TWI267378B (en) | 2001-06-08 | 2006-12-01 | Wyeth Corp | Calcium phosphate delivery vehicles for osteoinductive proteins |
| WO2003066000A2 (en) * | 2002-02-08 | 2003-08-14 | Wyeth | Formulation comprising bioactive agents and method of using same |
| AU2003208196A1 (en) * | 2002-02-22 | 2003-09-09 | Biomatera Inc. | Biodegradable bone implant |
| AU2003242976A1 (en) | 2002-07-16 | 2004-02-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods of implanting mesenchymal stem cells for tissue repair and formation |
| US20040023322A1 (en) * | 2002-08-01 | 2004-02-05 | Goodheart Clyde R. | Method of producing non-recombinant BMP-2 and use thereof |
| US20050048099A1 (en) * | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
| US20050003007A1 (en) * | 2003-07-02 | 2005-01-06 | Michele Boix | Method of sterilization of polymeric microparticles |
| US7141544B2 (en) * | 2003-10-10 | 2006-11-28 | Baxter International, Inc. | Stabilization of pharmaceutical protein formulations with small peptides |
| US20060141049A1 (en) * | 2003-11-12 | 2006-06-29 | Allergan, Inc. | Triamcinolone compositions for intravitreal administration to treat ocular conditions |
| US20070224278A1 (en) * | 2003-11-12 | 2007-09-27 | Lyons Robert T | Low immunogenicity corticosteroid compositions |
| US20050250737A1 (en) * | 2003-11-12 | 2005-11-10 | Allergan, Inc. | Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods |
| US20050101582A1 (en) * | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
| BRPI0506983A (en) | 2004-01-20 | 2007-07-03 | Allergan Inc | localized eye therapy compositions, preferably comprising triamcinolone acetonide and hyaluronic acid |
| US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US20050244462A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Devices and methods for treating a mammalian eye |
| US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| US8591885B2 (en) * | 2004-04-30 | 2013-11-26 | Allergan, Inc. | Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems |
| US8119154B2 (en) * | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| US20050244466A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Photodynamic therapy in conjunction with intraocular implants |
| US8673341B2 (en) * | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
| US20050244458A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular neuropathies |
| US7771742B2 (en) | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| US8455656B2 (en) | 2004-04-30 | 2013-06-04 | Allergan, Inc. | Kinase inhibitors |
| US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
| US20070059336A1 (en) * | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
| US8512738B2 (en) | 2004-04-30 | 2013-08-20 | Allergan, Inc. | Biodegradable intravitreal tyrosine kinase implants |
| US20050244471A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Estradiol derivative and estratopone containing sustained release intraocular implants and related methods |
| US20050244461A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Controlled release drug delivery systems and methods for treatment of an eye |
| US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| US20050244478A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Anti-excititoxic sustained release intraocular implants and related methods |
| WO2005110374A1 (en) * | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
| US8147865B2 (en) * | 2004-04-30 | 2012-04-03 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| US8425929B2 (en) | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
| ATE462451T1 (en) * | 2004-06-16 | 2010-04-15 | Affinergy Inc | INTERFACE BIOMATERIALS TO PROMOTE ADHESION OF TARGET ANALYTES |
| WO2006033698A2 (en) * | 2004-07-12 | 2006-03-30 | Isto Technologies, Inc. | Tissue matrix system |
| WO2006017347A2 (en) * | 2004-07-12 | 2006-02-16 | Allergan, Inc. | Opthalmic compositions and methods for treating ophthalmic conditions |
| US8512730B2 (en) * | 2004-07-12 | 2013-08-20 | Isto Technologies, Inc. | Methods of tissue repair and compositions therefor |
| US20060258578A1 (en) * | 2005-05-10 | 2006-11-16 | The University Of Zurich | Pharmaceutical composition |
| US20060286171A1 (en) * | 2005-06-17 | 2006-12-21 | Tianhong Zhou | Bone morphogenetic protein formulations |
| US8444968B2 (en) * | 2005-12-07 | 2013-05-21 | Isto Technologies, Inc. | Cartilage repair methods |
| US20070178138A1 (en) * | 2006-02-01 | 2007-08-02 | Allergan, Inc. | Biodegradable non-opthalmic implants and related methods |
| US7754689B2 (en) | 2006-06-02 | 2010-07-13 | Wyeth Llc | Finger-1 peptide analogs of the TGF-β superfamily |
| CA2654181A1 (en) | 2006-06-02 | 2007-12-13 | Wyeth | Use of proteins and peptides of the tgf-beta superfamily for purification and therapeutic methods |
| US8802128B2 (en) * | 2006-06-23 | 2014-08-12 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| US20070298073A1 (en) * | 2006-06-23 | 2007-12-27 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| DE102006060958A1 (en) * | 2006-12-20 | 2008-06-26 | Jennissen, Herbert P., Prof. Dr. | Process for the preparation of a polymer matrix, implants made thereof and their use |
| US7911053B2 (en) * | 2007-04-19 | 2011-03-22 | Marvell World Trade Ltd. | Semiconductor packaging with internal wiring bus |
| JP5824212B2 (en) * | 2007-05-15 | 2015-11-25 | ストライカー コーポレイションＳｔｒｙｋｅｒ Ｃｏｒｐｏｒａｔｉｏｎ | Bone morphogenetic protein concentrated protein preparation and method of use thereof |
| DE102007051914A1 (en) * | 2007-10-29 | 2009-05-07 | Herbert Prof. Dr. Jennissen | Process for the preparation of particles loaded with growth factors and the particles thus obtained |
| US8764350B2 (en) | 2008-06-05 | 2014-07-01 | Alstom Technology Ltd | Conveyor for transporting powder, and a method for conveying powder |
| EP2498783B1 (en) | 2009-11-09 | 2018-08-22 | Allergan, Inc. | Compositions and methods for stimulating hair growth |
| CA2798710C (en) | 2010-05-11 | 2019-08-27 | Venkat R. Garigapati | Organophosphorous, multivalent metal compounds, & polymer adhesive interpenetrating network compositions & methods |
| JP2012082180A (en) * | 2010-10-14 | 2012-04-26 | Nagoya Univ | Self-organizing peptide hydrogel for bone regeneration |
| WO2012158527A2 (en) | 2011-05-13 | 2012-11-22 | Howmedica Osteonics | Organophosphorous & multivalent metal compound compositions & methods |
| EP2851085B1 (en) * | 2012-05-14 | 2019-06-26 | Teijin Limited | Protein ccomposition sterilized by radiation |
| US10245306B2 (en) | 2012-11-16 | 2019-04-02 | Isto Technologies Ii, Llc | Flexible tissue matrix and methods for joint repair |
| CA2901280A1 (en) | 2013-02-15 | 2014-08-21 | Allergan, Inc. | Sustained drug delivery implant |
| CN106102733B (en) | 2014-03-20 | 2018-11-16 | 斯泰布尔治疗公司 | One kind is for the composition used in treatment interverbebral disc associated pain |
| US10179191B2 (en) | 2014-10-09 | 2019-01-15 | Isto Technologies Ii, Llc | Flexible tissue matrix and methods for joint repair |
| US10195305B2 (en) * | 2015-03-24 | 2019-02-05 | Orthovita, Inc. | Bioactive flowable wash-out resistant bone graft material and method for production thereof |
| MX2018003081A (en) | 2015-09-14 | 2018-05-07 | Stayble Therapeutics Ab | A composition for use in the treatment of intervertebral disc-related pain. |
| JP6901721B2 (en) * | 2017-03-30 | 2021-07-14 | 国立大学法人東海国立大学機構 | Bone marrow hemostatic agent |
| KR102066392B1 (en) | 2017-11-14 | 2020-01-16 | 한국치아은행 주식회사 | Method of manufacturing Bone-grafting complex and Bone-grafting complex manufactured thereby |
| CN109125791B (en) * | 2018-09-29 | 2019-08-30 | 广州贝奥吉因生物科技有限公司 | A kind of absorbable bone wax and preparation method with promotion Bone Defect Repari function |
| EP3936165A1 (en) * | 2020-07-10 | 2022-01-12 | MedPark Co., Ltd. | Method for preparing bone graft composition and bone graft composition |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3407076A (en) * | 1964-08-28 | 1968-10-22 | Hercules Inc | Protein-polymer complexes and process |
| GB1332505A (en) * | 1970-10-16 | 1973-10-03 | Ethicon Inc | Sutures and other surgical aids |
| US3991766A (en) * | 1973-05-31 | 1976-11-16 | American Cyanamid Company | Controlled release of medicaments using polymers from glycolic acid |
| US4033938A (en) * | 1974-01-21 | 1977-07-05 | American Cyanamid Company | Polymers of unsymmetrically substituted 1,4-dioxane-2,5-diones |
| EP0140255B1 (en) * | 1983-10-14 | 1991-05-15 | Sumitomo Pharmaceuticals Company, Limited | Sustained-release injections |
| JPS60100516A (en) * | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | Preparation of sustained release microcapsule |
| US4818542A (en) * | 1983-11-14 | 1989-04-04 | The University Of Kentucky Research Foundation | Porous microspheres for drug delivery and methods for making same |
| US4563489A (en) * | 1984-02-10 | 1986-01-07 | University Of California | Biodegradable organic polymer delivery system for bone morphogenetic protein |
| US4637931A (en) * | 1984-10-09 | 1987-01-20 | The United States Of America As Represented By The Secretary Of The Army | Polyactic-polyglycolic acid copolymer combined with decalcified freeze-dried bone for use as a bone repair material |
| ATE61935T1 (en) * | 1985-02-07 | 1991-04-15 | Takeda Chemical Industries Ltd | PROCESS FOR PRODUCTION OF MICROCAPSULES. |
| JPS62223112A (en) * | 1986-03-25 | 1987-10-01 | Rooto Seiyaku Kk | Remedy for periodontosis |
| IL83003A (en) * | 1986-07-01 | 1995-07-31 | Genetics Inst | Osteoinductive factors |
| US4877864A (en) * | 1987-03-26 | 1989-10-31 | Genetics Institute, Inc. | Osteoinductive factors |
| DE3624171A1 (en) * | 1986-07-17 | 1988-01-21 | Bosch Gmbh Robert | HEATING AND / OR AIR CONDITIONING FOR MOTOR VEHICLES |
| NL8702563A (en) * | 1987-10-28 | 1989-05-16 | Cca Biochem B V | POLYMER LACTIDE, METHOD FOR PREPARING SUCH A POLYMER LACTIDE, AND A COMPOSITION CONTAINING SUCH POLYMER LACTIDE. |
| JP2670680B2 (en) * | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | Polylactic acid microspheres containing physiologically active substance and method for producing the same |
| JP2548414B2 (en) * | 1988-04-08 | 1996-10-30 | ストライカー・コーポレーション | Biosynthetic bone morphogenetic protein and osteogenic device containing the protein |
| US4975526A (en) * | 1989-02-23 | 1990-12-04 | Creative Biomolecules, Inc. | Bone collagen matrix for zenogenic implants |
| US5108753A (en) * | 1988-04-08 | 1992-04-28 | Creative Biomolecules | Osteogenic devices |
| WO1989010409A1 (en) * | 1988-04-08 | 1989-11-02 | Genetics Institute, Inc. | Bone and cartilage inductive compositions |
| WO1990009783A1 (en) * | 1989-02-22 | 1990-09-07 | Massachusetts Institute Of Technology | Delivery system for controlled release of bioactive factors |
| ES2093647T3 (en) * | 1989-06-05 | 1997-01-01 | Massachusetts Inst Technology | BIOEROSIONABLE POLYMERS FOR THE RELEASE OF DRUGS IN THE BONES. |
| CA2024196A1 (en) * | 1990-06-13 | 1991-12-14 | Thomas M. S. Chang | Porous microbead permeable to macromolecules having immobilized therein at least one biological particulate |
| EP0489743A1 (en) * | 1990-07-03 | 1992-06-17 | Vipont Pharmaceutical, Inc. | Intragingival delivery systems for treatment of periodontal disease |
-
1992
- 1992-06-22 AT AT92914339T patent/ATE142460T1/en not_active IP Right Cessation
- 1992-06-22 AU AU22542/92A patent/AU663328B2/en not_active Ceased
- 1992-06-22 WO PCT/US1992/005309 patent/WO1993000050A1/en active IP Right Grant
- 1992-06-22 EP EP92914339A patent/EP0591392B1/en not_active Expired - Lifetime
- 1992-06-22 US US08/081,378 patent/US5597897A/en not_active Expired - Lifetime
- 1992-06-22 KR KR1019930703979A patent/KR0145278B1/en not_active IP Right Cessation
- 1992-06-22 ES ES92914339T patent/ES2094359T3/en not_active Expired - Lifetime
- 1992-06-22 DE DE69213739T patent/DE69213739T2/en not_active Expired - Fee Related
- 1992-06-22 DK DK92914339.4T patent/DK0591392T3/en active
- 1992-06-22 JP JP50162593A patent/JP3351525B2/en not_active Expired - Fee Related
- 1992-06-22 CA CA002111199A patent/CA2111199C/en not_active Expired - Fee Related
- 1992-06-22 MX MX9203083A patent/MX9203083A/en unknown
-
1993
- 1993-12-13 NO NO934573D patent/NO934573D0/en unknown
- 1993-12-13 NO NO934573A patent/NO307402B1/en not_active IP Right Cessation
- 1993-12-20 FI FI935732A patent/FI109274B/en active
-
1996
- 1996-11-14 GR GR960402998T patent/GR3021627T3/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO934573L (en) | 1993-12-13 |
| FI935732A (en) | 1993-12-20 |
| AU663328B2 (en) | 1995-10-05 |
| NO934573D0 (en) | 1993-12-13 |
| KR0145278B1 (en) | 1998-07-15 |
| FI109274B (en) | 2002-06-28 |
| DE69213739D1 (en) | 1996-10-17 |
| AU2254292A (en) | 1993-01-25 |
| WO1993000050A1 (en) | 1993-01-07 |
| CA2111199A1 (en) | 1993-01-07 |
| FI935732A0 (en) | 1993-12-20 |
| JPH06508777A (en) | 1994-10-06 |
| GR3021627T3 (en) | 1997-02-28 |
| US5597897A (en) | 1997-01-28 |
| ATE142460T1 (en) | 1996-09-15 |
| DE69213739T2 (en) | 1997-02-20 |
| DK0591392T3 (en) | 1996-09-30 |
| ES2094359T3 (en) | 1997-01-16 |
| EP0591392B1 (en) | 1996-09-11 |
| NO307402B1 (en) | 2000-04-03 |
| JP3351525B2 (en) | 2002-11-25 |
| EP0591392A1 (en) | 1994-04-13 |
| MX9203083A (en) | 1994-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2111199C (en) | Pharmaceutical formulations of osteogenic proteins | |
| EP0608313B1 (en) | Formulations of blood clot-polymer matrix for delivery of osteogenic proteins | |
| CA2169362C (en) | Formulations for delivery of osteogenic proteins | |
| AU774427B2 (en) | Formulations of hyaluronic acid for delivery of osteogenic proteins | |
| US5520923A (en) | Formulations for delivery of osteogenic proteins | |
| Kempen et al. | Retention of in vitro and in vivo BMP-2 bioactivities in sustained delivery vehicles for bone tissue engineering | |
| EP1220693B1 (en) | Formulations for delivery of osteogenic proteins | |
| EP1454640A2 (en) | Formulations of hyaluronic acid for delivery of osteogenic proteins | |
| AU8023000B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |